By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



8 rue de la Croix Jarry

Paris    75013  France
Phone: 33-0-1-81-69-16-00 Fax: n/a




Company News
Servier Exercises Exclusive Worldwide Licensing Option With Cellectis (ALCLS) For UCART19, An Allogeneic CAR-T Cell Therapy For Hematological Malignancies 11/19/2015 11:58:48 AM
Pfizer (PFE), Servier Snap Up Right to Cellectis (ALCLS)' Blood Cancer Therapy in $338 Million+ Deal 11/19/2015 5:57:59 AM
Cellectis (ALCLS) Reports Third Quarter And First Nine Months 2015 Financial Results 11/17/2015 11:05:36 AM
Cellectis (ALCLS) To Present Data On Its Allogeneic CAR T-Cell Immunotherapy Product Candidates During The Upcoming American Society of Hematology Annual Meeting 11/6/2015 11:37:32 AM
Cellectis (ALCLS): UCART19: First In Man Proof Of Concept To Be Presented At 2015 American Society of Hematology Annual Meeting 11/5/2015 1:03:28 PM
Cellectis (ALCLS) Release: Successful GMP Production Process For UCART19 10/29/2015 1:31:52 PM
Cellectis (ALCLS) Announces Presentations At Upcoming Conferences 9/10/2015 10:30:03 AM
Cellectis (ALCLS) Reports Second Quarter And First Half Year 2015 Financial Results 9/9/2015 10:46:18 AM
MD Anderson Cancer Center And Cellectis (ALCLS) Announce A Broad Preclinical And Clinical Strategic Alliance In Cancer Immunotherapy 9/4/2015 9:12:31 AM
Cellectis (ALCLS) To Present Data On Its CAR T-Cell Immunotherapy Programs During Upcoming Conferences 8/27/2015 8:02:21 AM